Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance

MARAVAI LIFESCIENCES HOLDINGS, INC.

2026-Q1 EPS reported -$0.02 revenue$65,837,000

Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.
Adjusted EBITDA of $20.3M vs $(10.5)M prior year; generated $4.2M free cash flow.
TriLink revenue up 65.1% to $47.5M, driven by $14.3M COVID CleanCap orders; base TriLink up 15.4%.
Cygnus revenue $18.4M, up 1.4% due to strong North America/EMEA, offset by China timing.
Full-year 2026 revenue and Adjusted EBITDA guidance raised reflecting Q1 strength and improved visibility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MARAVAI LIFESCIENCES HOLDINGS, INC. reported first quarter ended March 31, 2026 results: revenue $65.8 million, net income $(6.4) million. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $65.8 million
Net income: $(6.4) million
Guidance: raised
Result: reported results

Exact text from the filing

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: • Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million;

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-26-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.